FA decrease in 5STS impaired participants. by Charlotte Bernard (433013)

Zebrafish PGRP5 exhibits differential expression characteristics under different bacterial stimuli. by Xi Li (19208)

Chronic high glucose induces apoptosis and proteasome activities decrease in INS-1E cells. by Christophe Broca (538652)

Chronic high glucose induces apoptosis and proteasome activities decrease in INS-1E cells. by Christophe Broca (538652)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Blocking C5L2 decreased C5a-primed neutrophils expression of membrane-bound PR3 (mPR3). by Jian Hao (160736)

A. We randomly selected 20 mutually exclusive groups of protein complexes that contained exactly five subunits; we mapped the corresponding gene pairs to SINaTRA scores, and plotte... by Alexandra Jacunski (5665486)

“…B. We compared the SINaTRA scores of gene pairs with products in the same vs. different complexes for complexes with of 5 protein subunits (top), ≤10 proteins (middle), and any number (bottom). …”

(a) Schematics of water tunnel and (b) Experimental setup. by Muhammad Hammad Bucha (21736111)

Subjects:

DataSheet_1_Imiquimod Boosts Interferon Response, and Decreases ACE2 and Pro-Inflammatory Response of Human Bronchial Epithelium in Asthma.pdf by Juan José Nieto-Fontarigo (11800142)

“…We sought to investigate if imiquimod, a TLR7 agonist, exhibits such dual actions in ex vivo cultured human bronchial epithelial cells (HBECs), targets for SARS-CoV-2 infectivity.…”

GAS5 levels are decreased in bladder cancer. by Zhihong Liu (112690)

Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization by figshare admin karger (2628495)

“…Participants were categorized by LVEDD change from baseline: No Change (<5 mm), Decreased (≥5 mm), and Increased (≥5 mm). …”

Scara5 expression decreased during retinopathy. by Luísa Mendes-Jorge (635136)

“…C: The immunolabeling of paraffin-embedded retinal sections with anti-Scara5 antibody confirmed that Scara5 expression decreased throughout the parenchyma. …”

Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice by Michael T Buckley (37161)

“…Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”

Resistance to Pap-A correlates with decreases in PS. by Chelsi D. Cassilly (2793433)